Excellent news, animal trials starting and to be finished early 2019.
"“The further we get down the road, the more viable the project becomes and the greater our chances are of securing a commercial partnership to bring it to market.... "
This strategy is much more conducive to shareholder value than the go it alone approach the old board followed with cardiocel
Ann: TAVR project progresses to animal trials, page-3
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.28 |
Change
-0.520(4.41%) |
Mkt cap ! $238.2M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $11.85 | $11.27 | $180.4K | 15.55K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 42 | $11.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.45 | 245 | 1 |
View Market Depth
| Last trade - 13.42pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |